






















Journal of the American College of Cardiology Vol. 45, No. 4, 2005
© 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00
PMini-Focus: Transcatheter Closure of ASD and PFO
ssociation of Interatrial
hunts and Migraine Headaches
mpact of Transcatheter Closure
abak Azarbal, MD, Jonathan Tobis, MD, William Suh, MD, Vicki Chan, BA, Catherine Dao, BA,
ichard Gaster
os Angeles, California
OBJECTIVES To examine the relationship between patent foramen ovale (PFO) or atrial septal defect
(ASD) with the incidence of migraine headache (MHA) and assess whether closure of the
interatrial shunt in patients with MHA would result in improvement of MHA.
BACKGROUND Migraine headache is present in 12% of adults and has been associated with interatrial
communications. This study examined the relationship between PFO or ASD with the
incidence of MHA and assessed whether closure of the interatrial shunt in patients with
MHA would result in improvement of MHA.
METHODS A sample of 89 (66 PFO/23 ASD) adult patients underwent transcatheter closure of an
interatrial communication using the CardioSEAL (n 22), Amplatzer PFO (n 43), or the
Amplatzer ASD (n  24) device.
RESULTS Before the procedure, MHA was present in 42% of patients (45% of patients with PFO and
30% of patients with ASD). At three months after the procedure, MHA disappeared
completely in 75% of patients with MHA and aura and in 31% of patients with MHA
without aura. Of the remaining patients, 40% had significant improvement (2 grades by the
Migraine Disability Assessment Questionnaire) of MHA.
CONCLUSIONS Transcatheter closure of PFO or ASD results in complete resolution of MHA in 60% of
patients (75% of patients with migraine and aura) and improvement in symptoms in 40% of
the remaining patients. Interatrial communications may play a role in the etiology of MHA
either through paradoxic embolism or humoral factors that escape degradation in bypassing
the pulmonary circulation. A randomized trial is needed to determine whether transcatheter
closure of interatrial shunts is an effective treatment for MHA. (J Am Coll Cardiol 2005;






















uecause of increased associations, patent foramen ovale
PFO) has been implicated in the etiology of cryptogenic
troke secondary to paradoxic embolism (1,2), platypnea-
rthodeoxia syndrome (3,4), neurologic decompression ill-
ess in scuba divers (3,5–7), and migraine headache (MHA)
5,8–13), especially in patients with migraine and aura.
See page 496
The purpose of this study was to examine the relationship
etween the presence of MHA in patients with either PFO
iscovered during evaluation of cryptogenic cerebrovascular
ccident or an atrial septal defect (ASD), and whether
losure of these interatrial shunts had any effect on MHA.
ETHODS
atient population. A total of 102 consecutive adult pa-
ients underwent transcatheter closure of an interatrial
ommunication (26 ASD and 76 PFO) using the Amplatzer
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004, accepted September 28, 2004.FO device (AGAMedical, Minneapolis, Minnesota) (n
5), the CardioSEAL (NMT Medical, Inc., Boston, Mas-
achusetts) (n  30), or the Amplatzer atrial septal occluder
evice (n  27). Of the 102 patients with successful closure
f their interatrial communication, 97 were available for
ollow-up, and follow-up was obtained in 89 (92%).
rocedure. Patients were usually given aspirin (81 to 325
g daily) and clopidogrel (75 mg daily) a few days before
he procedure. When a patient had been taking warfarin, it
as discontinued four days before the procedure. Proce-
ures were performed without general anesthesia and on an
utpatient basis after August 2001. For PFO closures,
ransesophageal echocardiography (TEE) (n  65) (14) or
ntracardiac echo (n  11) (14–16) were used to guide the
rocedure to ensure that the device was optimally placed.
ll ASD closures were done with TEE guidance. Heparin
as routinely administered at the start of the procedure to
chieve an activated clotting time 250 s.
ollow-up evaluation. Patients were usually discharged
aking aspirin (325 mg daily) and clopidogrel (75 mg daily).
tandard endocarditis prophylaxis was prescribed. Warfarin
se in addition to antiplatelet therapy was determined by the
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mplantation.
efinitions of echocardiographic findings. The presence
f a residual shunt at follow-up TEE examination was
etermined by color-flow Doppler for left-to-right shunt
17) and by agitated saline contrast injection into an
ntecubital vein for the presence of right-to-left shunt (18).
esidual shunts were categorized into none, small, and
oderate to large by color Doppler flow and into none,
mall, moderate, and large by contrast injection. The pres-
nce or absence of an atrial septal aneurysm was determined
s previously described (19). The presence of thrombus on
he device in the follow-up period was defined as a new
ypoechogenic non-planar, partially mobile structure.
ssessment of migraine headaches. Presence or absence
f MHA was self-reported by patients on the basis of a
iagnosis made by either their primary care physician or
heir neurologist. Migraine severity was assessed by using
he previously validated Migraine Disability Assessment
uestionnaire (MIDAS) (20–23). The MIDAS score is
erived by adding up the number of functional days lost
ecause of MHA and is graded from 1 to 4.
tatistical analysis. Continuous variables were analyzed
sing t tests and dichotomous variables were analyzed using
hi-square tests. Continuous variables are expressed as mean
alues  SD and dichotomous variables are expressed as a
requency percentage. A p value of 0.05 was considered to
e statistically significant.
ESULTS
FO closure. Of 76 patients, 50 (66%) were women and
he mean age was 49  13 years old (range 17 to 77 years).
he majority of patients with PFO (52 of 76) had a PFO
lone (68%); an atrial septal aneurysm was associated with
he PFO in 24 patients (32%).
The CardioSEAL device was used in 30 patients, the
mplatzer PFO occluder device in 45 patients, and the
mplatzer septal occluder in 1 patient. A transseptal punc-
ure technique was used in 15 patients (20%) (24).
Transesophageal echocardiography follow-up was avail-
ble in 65 of 76 patients. The incidence of residual shunt did
ot differ between the CardioSEAL and the Amplatzer
evices (4 of 26, 15% vs. 8 of 39, 21%, p  0.27). All
esidual shunts were small (color Doppler jet 2 mm
hrough the defect or the presence of 3 to 9 microbubbles in
Abbreviations and Acronyms
ASD  atrial septal defect
MHA  migraine headache
MIDAS  Migraine Disability Assessment
Questionnaire
PFO  patent foramen ovale
TEE  transesophageal echocardiographyhe left atrium by contrast injection). The incidence of
M
nhrombus formation at one month was 22% in patients
eceiving the CardioSEAL device and 0% in patients
eceiving the Amplatzer PFO device (25).
SD closure. Of 26 patients with successful ASD closure,
he average age was 41  15 years, and 76% of these
atients were women. All ASD closures were accomplished
sing the Amplatzer septal occluder device under TEE
uidance. Transesophageal echocardiography follow-up was
vailable in 23 patients. There was no incidence of throm-
us formation on any of the devices. A small residual shunt
as present in 7 of 23 patients.
igraine headaches. Preoperatively, MHA was present in
7 of 89 (42%) patients (24 with aura and 13 without aura).
f these 37 patients with MHA who had successful
ranscatheter interatrial closure, 28 (76%) either had com-
lete resolution or significant improvement in their MHA.
ables 1 and 2 summarize the effect of closure of interatrial
ommunications on patients with known MHA. Postoper-
tively, MHA disappeared completely in 22 of 37 patients
able 1. Association of Migraine Headache With Interatrial








Any migraine 37 (42%) 30/66 (45%) 7/23 (30%)
MHA 24 (27%) 20/66 (30%) 4/23 (17%)
MHA 13 (15%) 10/66 (15%) 3/23 (13%)
ny improvement
Any migraine 28/37 (76%) 24/30 (80%) 4/7 (57%)
MHA 19/24 (79%) 16/20 (80%) 3/4 (75%)
MHA 9/13 (69%) 8/10 (80%) 1/3 (33%)
esolution
Any migraine 22/37 (60%) 19/30 (63%) 3/7 (43%)
MHA 18/24 (75%) 15/20 (75%) 3/4 (75%)
MHA 4/13 (31%) 4/10 (40%) 0/3
mprovement,
but no resolution
Any migraine 6/37 (16%) 5/30 (17%) 1/7 (14%)
MHA 1/24 (4%) 1/20 (5%) 0/4
MHA 5/13 (38%) 4/10 (40%) 1/3 (33%)
SD  atrial septal defect; MHA  migraine headache with aura; MHA 
igraine headache without aura; PFO  patent foramen ovale.
able 2. Pattern of Headache Improvement in Patients After
losure of Interatrial Communication
Before After p Value
HA episodes
Overall 12.4  27.7 2.2  5.4 0.004
Resolved completely 4.0  6.4 0 0.008
Did not resolve completely 24.7  31.5 5.5  7.4 0.02
HA severity (scale of 1–10)
Overall 6.4  10.7 3.7  5.1 0.0003
Resolved completely 6.6  10.1 0 0.0001
Did not resolve completely 6.2  3.2 5.8  2.7 0.7
IDAS score
Overall 19.1  47.1 5.2  26.6 0.08
Resolved completely 16.8  54.8 0 0.16
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n 4 of 13 patients (31%) with MHA without aura.
Of the remaining 15 patients, 6 (40%) had significant
mprovement of 2 grades in incidence and severity of
HA as assessed by the MIDAS questionnaire; there was
o difference in the effect on MHA in the patients treated
ith the CardioSEAL device versus those treated with the
mplatzer device or in patients with or without a small
esidual shunt.
ISCUSSION
he prevalence of MHA in the general population is 12%
26–28), but was 3.5 times higher (42%) in our patients
ith interatrial communications. The prominent finding of
his observational study is that transcatheter closure of PFO
r ASD results in complete resolution of MHA in the
ajority (60%) of patients and significant improvement (2
IDAS grades) in symptoms in a large portion (40%) of
he remaining patients (overall, 76% of MHA resolve or
mprove). In addition, this symptomatic improvement of
evere migraines persisted for the 12-month mean length of
ur follow-up. Our observations complement other reports
5,8–13) demonstrating an increased association of MHA
n patients with interatrial communications.
The association between closure of interatrial communi-
ation and improvement of headache appears to be stronger
ith migraine and aura than with migraine without aura. In
his population, 75% of patients with migraine with aura
ad complete resolution of their headache after successful
losure of the interatrial communication versus 31% of
atients with migraine headache without aura. However, a
ajority of patients (69%) with migraine without aura still
xperienced either a complete resolution of their migraine
eadache or significant improvement of 2 MIDAS
rades.
Based on the association of PFO, cryptogenic stroke, and
HA, several new hypotheses have been proposed for the
tiology of MHA. It has been postulated that a MHA is due
o a small venous embolus that crosses the PFO paradoxi-
ally and passes to the cerebral circulation. Rather than
nducing a stroke, the small embolus or platelet plug
recipitates a spreading wave of depolarization that is
ecognized as the neurologic phenomenon of migraine. In
upport of this theory, one recent study demonstrated a
3.7-fold higher incidence of magnetic resonance imaging
esions in migraine patients with aura than in controls (29).
Alternatively, we hypothesize that migraine is precipi-
ated in susceptible individuals by chemical substances that
an pass directly through the atrial shunt before they can be
etoxified in their first passage through the lungs. This
ubstance, in elevated concentration, could cause migraine
n susceptible individuals without a PFO, but if a PFO is
resent it could potentially shunt from the venous to the
rterial system and reach the brain in a more concentrated
acket than if a central shunt were not present. In thisypothesis, the presence of a PFO also predisposes to
aradoxic embolism and stroke and is the pathway for
mboli that produce the magnetic resonance imaging lesions
een in patients with MHA (29). The “migraine stroke” is
robably not caused by intense vasospasm, but may be a
anifestation of a paradoxical embolism through a PFO.
Whatever theory of MHA is eventually validated, the
rofound improvement in this debilitating condition by
losure of an interatrial shunt, as observed in these patients,
aises the possibility of providing a substantive treatment for
evere MHA. A prospective randomized trial is justified to
etermine whether closure of PFO in patients with MHA
eads to significant reduction in the incidence of migraine
ompared to medical therapy.
tudy limitations. This study was a retrospective evalua-
ion and not a prospective randomized trial. The patient
roup being studied consisted primarily of patients with a
istory of cryptogenic stroke with a known interatrial
ommunication and is not representative of the general
opulation of patients with PFO. Although the MIDAS
uestionnaire is a well-established tool in the evaluation of
he severity of MHA, it is a subjective method. All patients
ere taking clopidrogel for three months and taking aspirin
ndefinitely after closure of their interatrial communication;
herefore, improvement in MHA could be attributed in part
o use of these medications.
onclusions. There is a 3.5-fold increased incidence of
HA in patients with a PFO or ASD who are undergoing
ranscatheter closure of their interatrial communication.
ranscatheter closure of PFO or ASD in patients with
HA leads to resolution of or significant improvement in
everity of MHA in the majority (76%) of patients. A
rospective randomized trial is justified to determine
hether closure of PFO in patients with MHA leads to
ignificant reduction in the incidence of migraine compared
ith medical therapy.
eprint requests and correspondence: Dr. Jonathan Tobis,
rofessor of Medicine, Department of Internal Medicine (Divi-
ion of Cardiology), 47-123 Center for Health Sciences, 650
harles E. Young Drive South, Los Angeles, California 90095.
-mail: jtobis@mednet.ucla.edu.
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